company background image
6628

Transcenta Holding SEHK:6628 Stock Report

Last Price

HK$3.75

Market Cap

HK$1.7b

7D

-1.6%

1Y

n/a

Updated

11 Aug, 2022

Data

Company Financials +
6628 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth1/6
Past Performance0/6
Financial Health5/6
Dividends0/6

6628 Stock Overview

Transcenta Holding Limited, a clinical stage biopharmaceutical company, engages in the discovery, research, development, manufacture, and commercialization of various drugs in the People’s Republic of China and the United States.

Transcenta Holding Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Transcenta Holding
Historical stock prices
Current Share PriceHK$3.75
52 Week HighHK$16.18
52 Week LowHK$3.72
Beta0
1 Month Change-16.85%
3 Month Change-25.00%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-71.68%

Recent News & Updates

Shareholder Returns

6628HK BiotechsHK Market
7D-1.6%0.8%-0.6%
1Yn/a-54.2%-23.8%

Return vs Industry: Insufficient data to determine how 6628 performed against the Hong Kong Biotechs industry.

Return vs Market: Insufficient data to determine how 6628 performed against the Hong Kong Market.

Price Volatility

Is 6628's price volatile compared to industry and market?
6628 volatility
6628 Average Weekly Movement6.5%
Biotechs Industry Average Movement7.9%
Market Average Movement6.5%
10% most volatile stocks in HK Market12.8%
10% least volatile stocks in HK Market3.1%

Stable Share Price: 6628 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: 6628's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2010363Xueming Qianhttps://www.transcenta.com

Transcenta Holding Limited, a clinical stage biopharmaceutical company, engages in the discovery, research, development, manufacture, and commercialization of various drugs in the People’s Republic of China and the United States. The company develops MSB2311, a humanized PD-L1 monoclonal antibody (mAb) candidate for TMB-H solid tumors; TST001, a humanized claudin 18.2 mAb candidate for solid tumors, such as gastric cancer and is under Phase II clinical trial; TST005, a PD-L1/TGF-ß bi-functional antibody candidate which is under Phase Ia clinical trial for solid tumors, including certain lung cancers; TST010, an antibody candidate targeting regulatory T cells to enhance T cell mediated tumor killing;TST002 (Blosozumab), a humanized sclerostin mAb candidate for osteoporosis; and TST004, a humanized mannan-binding lectin serine protease 2 (MASP 2) mAb candidate for IgA kidney diseases. It also develops TST003, an antibody candidate targeting a novel immune regulatory protein produced by tumor-associated fibroblasts or tumor cells with mesenchymal phenotype; TST006, a bi-specific claudin 18.2/PD-L1 antibody; TST008, a tri-functional antibody combining a MASP2 antibody fused with a truncated transmembrane activator and CAML interactor protein; MSB0254, a humanized VEGFR-2 mAb candidate for solid tumors and is under Phase Ib/IIa clinical trials; and MSB2311, A humanized PD-L1 mAb Candidate for solid tumors and is under Phase Ib/IIa clinical trials Transcenta Holding Limited has collaboration agreements with Eli Lilly and Company, Alebund Pharmaceuticals, and Merck.

Transcenta Holding Fundamentals Summary

How do Transcenta Holding's earnings and revenue compare to its market cap?
6628 fundamental statistics
Market CapCN¥1.44b
Earnings (TTM)-CN¥1.72b
Revenue (TTM)CN¥50.24m

28.6x

P/S Ratio

-0.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
6628 income statement (TTM)
RevenueCN¥50.24m
Cost of RevenueCN¥40.87m
Gross ProfitCN¥9.37m
Other ExpensesCN¥1.72b
Earnings-CN¥1.72b

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-3.85
Gross Margin18.65%
Net Profit Margin-3,414.56%
Debt/Equity Ratio17.8%

How did 6628 perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is 6628 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6628?

Other financial metrics that can be useful for relative valuation.

6628 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue10.6x
Enterprise Value/EBITDA-1.2x
PEG Ration/a

Price to Sales Ratio vs Peers

How does 6628's PS Ratio compare to its peers?

6628 PS Ratio vs Peers
The above table shows the PS ratio for 6628 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average21.4x
1061 Essex Bio-Technology
1.2x17.0%HK$2.0b
1228 CANbridge Pharmaceuticals
38x51.7%HK$1.4b
1875 TOT BIOPHARM International
24.9x50.7%HK$2.2b
2181 Mabpharm
21.8xn/aHK$2.1b
6628 Transcenta Holding
28.6x17.8%HK$1.7b

Price-To-Sales vs Peers: 6628 is expensive based on its Price-To-Sales Ratio (28.6x) compared to the peer average (21.4x).


Price to Earnings Ratio vs Industry

How does 6628's PE Ratio compare vs other companies in the HK Biotechs Industry?

Price-To-Sales vs Industry: 6628 is expensive based on its Price-To-Sales Ratio (28.6x) compared to the Hong Kong Biotechs industry average (27.4x)


Price to Sales Ratio vs Fair Ratio

What is 6628's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6628 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio28.6x
Fair PS Ratio2.5x

Price-To-Sales vs Fair Ratio: 6628 is expensive based on its Price-To-Sales Ratio (28.6x) compared to the estimated Fair Price-To-Sales Ratio (2.5x).


Share Price vs Fair Value

What is the Fair Price of 6628 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 6628's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 6628's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies

Future Growth

How is Transcenta Holding forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

1/6

Future Growth Score 1/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


31.7%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 6628 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 6628 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 6628 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 6628's revenue (17.8% per year) is forecast to grow faster than the Hong Kong market (10% per year).

High Growth Revenue: 6628's revenue (17.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 6628 is forecast to be unprofitable in 3 years.


Discover growth companies

Past Performance

How has Transcenta Holding performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-441.8%

Last years earnings growth

Earnings and Revenue History

Quality Earnings: 6628 is currently unprofitable.

Growing Profit Margin: 6628 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if 6628's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare 6628's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 6628 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (9.3%).


Return on Equity

High ROE: 6628 has a negative Return on Equity (-87.28%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Transcenta Holding's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: 6628's short term assets (CN¥1.4B) exceed its short term liabilities (CN¥425.8M).

Long Term Liabilities: 6628's short term assets (CN¥1.4B) exceed its long term liabilities (CN¥153.6M).


Debt to Equity History and Analysis

Debt Level: 6628 has more cash than its total debt.

Reducing Debt: Insufficient data to determine if 6628's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 6628 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: 6628 has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 3.9% each year.


Discover healthy companies

Dividend

What is Transcenta Holding current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate 6628's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 6628's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 6628's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 6628's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 6628 has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.5yrs

Average management tenure


CEO

Xueming Qian (53 yo)

no data

Tenure

CN¥5,174,000

Compensation

Dr. Xueming Qian, Ph.D. has been Chief Executive Officer and Executive Director at Transcenta Holding Limited. He was the Founder, Chairman and Chief Executive Officer of MabSpace Biosciences Co., Ltd. Dr....


CEO Compensation Analysis

Compensation vs Market: Xueming's total compensation ($USD767.13K) is above average for companies of similar size in the Hong Kong market ($USD305.74K).

Compensation vs Earnings: Xueming's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: 6628's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.


Board Members

Experienced Board: 6628's board of directors are not considered experienced ( 0.9 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: 6628 insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: 6628 only recently listed within the past 12 months.


Top Shareholders

Company Information

Transcenta Holding Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Transcenta Holding Limited
  • Ticker: 6628
  • Exchange: SEHK
  • Founded: 2010
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: HK$1.670b
  • Shares outstanding: 445.33m
  • Website: https://www.transcenta.com

Number of Employees


Location

  • Transcenta Holding Limited
  • B6-501, 218 Xinghu Street
  • Biobay
  • Suzhou
  • Jiangsu Province
  • 215123
  • China

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/11 00:00
End of Day Share Price2022/08/11 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.